Citrate-based acid concentrate for dialysis: 0.8 mmol/L citric acid and 0.3 mmol/L acetate (vs. 3 mmol/L acetate in standard concentrates). Citrate’s anticoagulant properties improve biocompatibility, reduce hypotension, and lower heparin use.
Overview
CITRASATE™ is an acid concentrate for dialysis with 0.8 mmol/l of citric acid and 0.3 mmol/l of acetate instead of the traditional 3 mmol/l of acetate in standard concentrates. 1+44 mixing ratio. Available in bags, canisters, politainers, and bag-in-box. Manufactured in Germany.
Benefits
- Improved biocompatibility and dialysis adequacy
- Reduced heparin use (up to 50%)
- 23% reduction in intradialytic hypotension
- Up to 33% higher long-term survival
- Correction of acidosis
- Improved nutritional state
Specifications
- Composition: 0.8 mmol/l citric acid + 0.3 mmol/l acetate
- Dilution: 1+44
- Shelf life: 35 months
- Packaging: bags, canisters, politainers, and bag-in-box
Download the CITRASATE™ Catalog (PDF)
Not all products are registered and approved for sale in all countries or regions. Other acid types and packaging units may be available on request.